Expert Interview
A Second Opinion: Reviewing the FDA Breakthrough Device Designation for Roche's Elecsys® Amyloid Plasma Panel for Alzheimer's Disease detection
Ticker(s): RHHBY, LLYInstitution: University of Kansas
- Director of NIH-funded University of Kansas Alzheimer's Disease Center.
- Currently manages 300 patients with Alzheimer's disease and very familiar with the Aducanumab public literature.
- Research is focused on brain energy metabolism, the role brain energy metabolism plays in Alzheimer's Disease, and how to manipulate brain energy metabolism.
Describe your background and practice setting
How many patients with Alzheimer's disease do you manage?
Added By: ben_adminWhat is the gold standard for Alzheimer's diagnosis currently?
Added By: ben_adminWhat is your opinion on the potential of Roche's Amyloid Plasma Panel?
Added By: ben_adminWhat patients would you order this panel for?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
